October 15, 2018
Stockholm - October 15, 2018 - According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on 17 May 2018, the Nomination Committee for the annual general meeting 2019 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of 28 September, along with the Chairman of the Board of Directors.
The composition of the Nomination Committee has now been established, and Oncopeptides today announced that the Nomination Committee in respect of the annual general meeting 2019 consists of the following persons who together represent approximately 55 percent of the number of shares and votes in the company based on the last known shareholder information at end September.
Staffan Lindstrand, appointed by HealthCap VI L.P.
Nina Rawal, appointed by Stiftelsen Industrifonden
Max Mitteregger, appointed by GLADIATOR
Per Wold-Olsen, the Chairman of the Board
The Nomination Committee’s proposals will be presented in the Notice to the annual general meeting 2019 and on Oncopeptides’ web site, www.oncopeptides.com.
Shareholders who wishes to submit proposals to the Nomination Committee can do so by sending an e-mail to firstname.lastname@example.org (subject “Nomination Committee”) or by letter posted to Oncopeptides AB, Attn: Oncopeptides Nomination Committee, Luntmakargatan 46, SE-111 37 Stockholm, Sweden.
A proposal must reach the nomination committee no later than by April 1st to be included in the notice to attend and the agenda for the annual general meeting.
The information was submitted for publication at 09.00 CET on October 15, 2018.
Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company focus on the development of the lead product candidate melflufen (Ygalo®), an alkylating peptide, Peptidase Enhanced Compounds (PEnCs). Melflufen (Ygalo®) is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from treatment with melflufen (Ygalo®) compared with established alternative drugs for patients with late-stage multiple myeloma. Melflufen (Ygalo®) will potentially provide physicians with a new treatment option for patients suffering from this serious disease.
Visit www.oncopeptides.com for more information.